TY - JOUR
T1 - Update 2020
T2 - Management of Non-Small Cell Lung Cancer
AU - Alexander, Mariam
AU - Kim, So Yeon
AU - Cheng, Haiying
N1 - Funding Information:
Mariam Alexander and So Yeon Kim do not have any conflicts of interest to disclose. Haiying Cheng has received research funding from Genentech/Roche, Eisai, Spectrum, Regeneron, Bayer, and Vaccinex.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/12
Y1 - 2020/12
N2 - The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.
AB - The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.
KW - Immune checkpoint inhibitors
KW - Lung cancer
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85095985813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095985813&partnerID=8YFLogxK
U2 - 10.1007/s00408-020-00407-5
DO - 10.1007/s00408-020-00407-5
M3 - Review article
C2 - 33175991
AN - SCOPUS:85095985813
SN - 0341-2040
VL - 198
SP - 897
EP - 907
JO - Lung
JF - Lung
IS - 6
ER -
